Anti-interferon gamma-inducible protein 16 antibodies Identification of a novel autoantigen in idiopathic interstitial pneumonia and its clinical characteristics based on a multicenter cohort study

Anti-interferon gamma-inducible protein 16 antibodies : Identification of a novel autoantigen in idiopathic interstitial pneumonia and its clinical characteristics based on a multicenter cohort study

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 268(2024) vom: 02. Nov., Seite 110372
Auteur principal: Sasai, Tsuneo (Auteur)
Autres auteurs: Nakashima, Ran, Handa, Tomohiro, Yamano, Yasuhiko, Kondo, Yasuhiro, Matsuda, Shogo, Kotani, Takuya, Tomioka, Hiromi, Tachikawa, Ryo, Tomii, Keisuke, Tanizawa, Kiminobu, Nohda, Yasuhiro, Kogame, Toshiaki, Shirakashi, Mirei, Hiwa, Ryosuke, Tsuji, Hideaki, Akizuki, Shuji, Yoshifuji, Hajime, Mimori, Tsuneyo, Kabashima, Kenji, Morinobu, Akio
Format: Article en ligne
Langue:English
Publié: 2024
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Multicenter Study Autoantibody Interferon gamma-inducible protein 16 Interstitial lung disease Interstitial pneumonia with autoimmune features Autoantigens Autoantibodies Phosphoproteins Nuclear Proteins plus... IFI16 protein, human 148998-64-5 Immunosuppressive Agents
LEADER 01000caa a22002652c 4500
001 NLM378442686
003 DE-627
005 20250507181526.0
007 cr uuu---uuuuu
008 241003s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2024.110372  |2 doi 
028 5 2 |a pubmed25n1287.xml 
035 |a (DE-627)NLM378442686 
035 |a (NLM)39357632 
035 |a (PII)S1521-6616(24)00481-9 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Sasai, Tsuneo  |e verfasserin  |4 aut 
245 1 0 |a Anti-interferon gamma-inducible protein 16 antibodies  |b Identification of a novel autoantigen in idiopathic interstitial pneumonia and its clinical characteristics based on a multicenter cohort study 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 04.11.2024 
500 |a Date Revised 21.01.2025 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved. 
520 |a Autoantibodies are detected in idiopathic interstitial pneumonias (IIPs) without a clear connective tissue disease diagnosis, and their clinical significance is unclear. This study aimed to identify a novel autoantibody in IIPs. We screened 295 IIP patients using a 35S-methionine labeled protein immunoprecipitation assay. Candidate autoantigens were identified via protein array and confirmed by immunoprecipitation. Six sera from 295 IIP patients immunoprecipitated common tetrameric proteins (100 kDa). The protein array identified interferon gamma-inducible protein 16 (IFI16) as the candidate autoantigen. Patients with anti-IFI16 antibodies received immunosuppressants less frequently. Five-year survival rates were 50 %, 69 %, and 63 % (P = 0.60), and acute exacerbation-free rates were 50 %, 96 %, and 84 % (P = 0.15) for patients with anti-IFI16, anti-aminoacyl tRNA antibodies, and others. Anti-IFI16 is a novel autoantibody in IIPs. Patients with this antibody often receive less immunosuppressive therapy and could have a poor prognosis. Further research is needed to refine patient stratification and management 
650 4 |a Journal Article 
650 4 |a Multicenter Study 
650 4 |a Autoantibody 
650 4 |a Interferon gamma-inducible protein 16 
650 4 |a Interstitial lung disease 
650 4 |a Interstitial pneumonia with autoimmune features 
650 7 |a Autoantigens  |2 NLM 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Phosphoproteins  |2 NLM 
650 7 |a Nuclear Proteins  |2 NLM 
650 7 |a IFI16 protein, human  |2 NLM 
650 7 |a 148998-64-5  |2 NLM 
650 7 |a Immunosuppressive Agents  |2 NLM 
700 1 |a Nakashima, Ran  |e verfasserin  |4 aut 
700 1 |a Handa, Tomohiro  |e verfasserin  |4 aut 
700 1 |a Yamano, Yasuhiko  |e verfasserin  |4 aut 
700 1 |a Kondo, Yasuhiro  |e verfasserin  |4 aut 
700 1 |a Matsuda, Shogo  |e verfasserin  |4 aut 
700 1 |a Kotani, Takuya  |e verfasserin  |4 aut 
700 1 |a Tomioka, Hiromi  |e verfasserin  |4 aut 
700 1 |a Tachikawa, Ryo  |e verfasserin  |4 aut 
700 1 |a Tomii, Keisuke  |e verfasserin  |4 aut 
700 1 |a Tanizawa, Kiminobu  |e verfasserin  |4 aut 
700 1 |a Nohda, Yasuhiro  |e verfasserin  |4 aut 
700 1 |a Kogame, Toshiaki  |e verfasserin  |4 aut 
700 1 |a Shirakashi, Mirei  |e verfasserin  |4 aut 
700 1 |a Hiwa, Ryosuke  |e verfasserin  |4 aut 
700 1 |a Tsuji, Hideaki  |e verfasserin  |4 aut 
700 1 |a Akizuki, Shuji  |e verfasserin  |4 aut 
700 1 |a Yoshifuji, Hajime  |e verfasserin  |4 aut 
700 1 |a Mimori, Tsuneyo  |e verfasserin  |4 aut 
700 1 |a Kabashima, Kenji  |e verfasserin  |4 aut 
700 1 |a Morinobu, Akio  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 268(2024) vom: 02. Nov., Seite 110372  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:268  |g year:2024  |g day:02  |g month:11  |g pages:110372 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2024.110372  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 268  |j 2024  |b 02  |c 11  |h 110372